BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx to $572 from $446 and keeps a Buy rating on the shares after the company reported positive data from the ADHERE trial evaluating subcutaneous efgartigimod, or Vyvgart Hytrulo, in chronic inflammatory demyelinating polyneuropathy, or CIDP. In the firm’s view, a 67% responder rate suggests the potential for broad coverage of CIDP patients with efgartigimod, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- argenx raises $1.1 billion in gross proceeds in a global offering
- Immunovant price target raised to $34 at Stifel after Argenx data
- Argenx price target raised to $566 from $460 at Baird
- Argenx price target raised to $606 from $544 at Wells Fargo
- Argenx price target raised to $545 from $505 at Guggenheim